Cancer Biology

1075 Proteogenomic characterization of HBV-related hepatocellular carcinoma (HCC) using paired tumor and adjacent liver tissues identifies three subgroups with distinct features in metabolic reprogramming, microenvironment dysregulation, cell proliferation, and potential therapeutics.

1074 PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity.

1073 Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.

1072 Analyses of transcriptomes from patients with acute myeloid leukaemia identified frequently co-occurring mutations of IDH2 and SRSF2, which functional analyses showed to have distinct and coordinated leukaemogenic effects on the epigenome and RNA splicing.

1071 Inducing and exploiting vulnerabilities for the treatment of liver cancer.

1070 Aldh1b1 expression defines progenitor cells in the adult pancreas and is required for Kras-induced pancreatic cancer.

1069 α-Ketoglutarate links p53 to cell fate during tumour suppression.

1068 E-cadherin is required for metastasis in multiple models of breast cancer.

1067 Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastases.

1066 Collagen-binding ability improves serum albumin as an anti-cancer drug carrier, resulting in enhanced therapeutic efficacy.

1065 A biomimetic pancreatic cancer on-chip reveals endothelial ablation via ALK7 signaling.

1064 A cell-penetrating fluorescent marker is used to label cells in the metastatic tumour microenvironment, revealing a variety of cell types including parenchymal cells with lung stem-cell characteristics.

1063 Acyl-CoA-Binding Protein Drives Glioblastoma Tumorigenesis by Sustaining Fatty Acid Oxidation.

1062 Mesoporous Silica as a Versatile Platform for Cancer Immunotherapy.

1061 Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.

1060 Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes.

1059 Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.

1058 Repurposing dasatinib for diffuse large B cell lymphoma.

1057 Proper dosing and timing of EGFR TKI can trigger antitumor T cell responses and potentiate anti–PD-L1 immunotherapy.

1056 Intercellular interaction dictates cancer cell ferroptosis via NF2–YAP signalling.

Free Images for Presentation: sunipix SUNIPIX